Half-year report · Q2
9341.TEDINET S100URJX
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥8.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥970m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥971m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥971m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥815m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥626m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥815m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥629m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥8.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥8.2bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥6.3bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.7bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥2.2bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.9bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.8bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.0bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥589m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥577m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥232m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥94m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥126m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥336m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥377m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥107m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥45.79 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥97.35 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.37 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥45.44 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥96.5 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥35.08 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 76.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 32
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥271m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥271m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥64m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥964m |
| jpcrp040300-q2r_E38215-000Medical Platform Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E38215-000Medical Platform Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E38215-000Medical Platform Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E38215-000Smart Clinic Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E38215-000Smart Clinic Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E38215-000Smart Clinic Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥394m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥4.9bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥4.9bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥274m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥274m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥73m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥727m |
| jpcrp040300-q2r_E38215-000Medical Platform Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E38215-000Medical Platform Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E38215-000Medical Platform Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E38215-000Smart Clinic Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥983m |
| jpcrp040300-q2r_E38215-000Smart Clinic Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥983m |
| jpcrp040300-q2r_E38215-000Smart Clinic Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥153m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥3.7bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥3.7bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥4.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥4.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 447
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in investment activities | Prior1YTDDuration | -125845000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -231985000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | － | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | -300000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 100000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -14953000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -31943000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YTDDuration | 20250000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYTDDuration | 250000 | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | Prior1YTDDuration | 2868000 | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | CurrentYTDDuration | － | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -81000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | － | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -1412000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | － | JPY |
| Market change expenses fin cf | Prior1YTDDuration | － | JPY |
| Market change expenses fin cf | CurrentYTDDuration | -4000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 106671000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -335692000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 563000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | -307000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 558446000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 20803000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 3860506000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 5965579000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 4418953000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 5986382000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 821951000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 1028367000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 20647000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 35538000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | 12081000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 17253000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E38215-000MedicalPlatformBusinessReportableSegmentsMember | 2723449000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E38215-000SmartClinicBusinessReportableSegmentsMember | 982809000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 3706259000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 274426000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 3980686000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 3980686000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E38215-000MedicalPlatformBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E38215-000SmartClinicBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E38215-000MedicalPlatformBusinessReportableSegmentsMember | 2723449000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E38215-000SmartClinicBusinessReportableSegmentsMember | 982809000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |